The results indicated that COPB2 was significantly overexpressed in glioma tissues compared with nontumor tissues and that high COPB2 expression was correlated with higher WHO grade, shorter overall survival (OS) time, and several poor clinical prognostic variables. This evidence concerns the gene COPB2 and glioma.